Shield Therapeutics plc

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:17 2024-04-26 am EDT			5-day change	1st Jan Change
1.35 ^GBX	+10.20%		-8.47%	-79.85%

Feb. 22	Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024
Feb. 21	FTSE 100 takes hit ahead of FOMC minutes	AN

Shield Therapeutics changes reporting currency to US dollars

September 06, 2023 at 03:34 pm EDT

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Says it will change reporting currency to US dollars from pound sterling from 2023 results. Says the interim results for the first half of 2023 will include condensed and consolidated US dollar financial information for the period and full-year 2022.

Current stock price: 10.92 pence, up 1.6%

12-month change: down 14%

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Shield Therapeutics plc

Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024	Feb. 22
FTSE 100 takes hit ahead of FOMC minutes	Feb. 21	AN
Shield Therapeutics sinks as strong performance marred by data issues	Feb. 21	AN
Shield Therapeutics plc Announces Unaudited Sales Results for the Year Ended 31 December 2023	Feb. 21	CI
Shield Therapeutics hires former Akili leader as new CFO	Jan. 09	AN
Shield Therapeutics Names New CFO	Jan. 09	MT
Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024	Jan. 08	CI
Comptoir opens restaurant; Intercede wins contract	Dec. 07	AN
FTSE 100 Ends Higher Fueled by Energy Stocks	23-10-12	DJ
Shield Therapeutics Chief Financial Officer Rudolf to leave	23-10-12	AN
AIM WINNERS & LOSERS: Windward sees high contracting activity levels	23-10-12	AN
Shield Therapeutics CFO to Step Down	23-10-12	MT
Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023	23-10-12	CI
Aston Martin CEO ups stake; Alkemy's lithium deal	23-10-03	AN
Shield Therapeutics completes USD20 million SWK financing	23-10-03	AN
Shield Therapeutics Closes $20 Million Debt Facility with SWK Funding	23-10-03	MT
EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy	23-10-02	AN
Shield Therapeutics Raises $6 Million via Share Issue	23-09-29	MT
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index	23-09-28	DJ
Shield Therapeutics completes GBP5 million share placing	23-09-28	AN
Shield Therapeutics raises funds for US sales push as loss narrows	23-09-28	AN
Earnings Flash (STX.L) SHIELD THERAPEUTICS Posts H1 Revenue $4.3M	23-09-28	MT
Earnings Flash (STX.L) SHIELD THERAPEUTICS Reports H1 Loss $-0.00	23-09-28	MT
Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Shield Therapeutics changes reporting currency to US dollars	23-09-06	AN

Chart Shield Therapeutics plc

Duration

Period

More charts

Company Profile

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shield Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0135 GBP

Average target price

0.02 GBP

Spread / Average Target

+48.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHIELD THERAPEUTICS PLC	-79.85%	13.15M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs